Introduction {#Sec1}
============

Antiplatelet drug therapy reduces the risk of cardiovascular (CV) diseases in various patient populations. Aspirin use is supported with clinical evidence \[[@CR1]--[@CR3]\], but can cause adverse events, such as gastrointestinal (GI) injuries, even with a low-dose regimen \[[@CR4]\]. According to meta-analyses, aspirin therapy increases the risk of GI bleeding by 2.7-fold as compared with results for a control arm, while it reduces the risk of major CV events by approximately 20 % \[[@CR5]\]. These complications of GI bleeding are more complex than previously thought. Indeed, the risk of CV events increases in patients who have experienced major bleeding events within a year. Thus, GI bleeding may lead to a higher incidence of subsequent thrombotic events. The American Heart Association (AHA) recommends the use of low-dose aspirin (75--325 mg) for patients having a 10-year CV-event risk of 10 % or greater \[[@CR6]\]. The US Preventive Services Task Force also recommends prophylactic aspirin therapy to be limited to patients with a 5-year CV risk of 3 % or greater, claiming that prophylaxis may not be beneficial for patients at low CV-event risk because the net clinical benefit is not high enough \[[@CR7]\].

A limited amount of data is available for calculating the net clinical benefit in Japanese patients. Although it may not be directly comparable, data of the Western populations have indicated the overall relative risk of upper GI complications was 2.2 to 3.1 times higher in aspirin users than in non-aspirin users \[[@CR8]\], whereas the odds ratio (OR) of upper GI bleeding was 5.5 in Japanese aspirin users \[[@CR9]\]. The higher risk of GI bleeding in Japanese patients might be due to the higher prevalence of *Helicobacter pylori* infection in the elderly and those who smoke tobacco \[[@CR9], [@CR10]\].

We conducted the Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study to determine the prevalence of endoscopic gastroduodenal ulcer and erosion in Japanese patients receiving regular aspirin for cardioprotection, and to clarify the risk factor profile including the concurrent use of gastroprotective drugs. This paper reports the baseline data obtained at the entry of this study.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This MAGIC study was conducted as an observational study in Japan. The details of the study design were published elsewhere \[[@CR11]\]. Described briefly, the study consisted of high-risk CV patients taking low-dose aspirin for cardioprotection that were consecutively recruited from 63 nationwide institutions between April 2007 and September 2009. It was each investigator's discretion to judge "high risk of CV patients". Gastroduodenal ulcers and erosions were detected by endoscopy at enrollment. The study protocol was approved by the institutional review board in each institution. All participants signed the written informed consent. The present paper reports the baseline data of the enrollment.

Study population {#Sec4}
----------------

The study population included patients with CV disease taking aspirin (75--330 mg daily) for at least 1 month. It included participants aged 20 years or older, and excluded those with serious hepatic, renal or pulmonary disorders, active cancer, hypersensitivity to aspirin or salicylate derivatives, pregnancy, possible pregnancy or pregnancy being planned, and prior surgical resection of esophagus, stomach, or duodenum.

Baseline demographic information {#Sec5}
--------------------------------

Upon the study entry, data on each patient's age, sex, underlying CV disease (e.g., coronary artery disease, cerebrovascular disease, and atrial fibrillation), comorbidities (hypertension, hyperlipidemia, diabetes mellitus, and metabolic syndrome), smoking habit, alcohol and coffee consumption, aspirin dosage and formulations (buffered or enteric coated), use of concomitant drugs, and history of upper GI ulcer were collected. All the participants were tested for the presence of *H. pylori* antibody after signing informed consent. *H. pylori* antibody in blood sample was measured using Anti-*H. pylori* IgG assay kit (SRL Inc., Tokyo, Japan). The *H. pylori* antibody was considered positive if the antibody level was ≥10 U/mL. The information on history of *H. pylori* eradication was collected from the patient medical records, where the eradication therapy was not well defined. Therefore, the results of eradication therapy were excluded from analysis. Antiulcer drugs included proton pump inhibitors (PPI), histamine 2-receptor antagonists (H2RA), cytoprotective antiulcer drugs, or prostaglandin analog (PGA).

Endoscopic assessment {#Sec6}
---------------------

Gastroduodenal ulcers or erosions were detected by endoscopy and the diagnosis was confirmed by the endoscopic evaluation committee (see [Appendix](#Sec26){ref-type="sec"}). Gastroduodenal ulcer was defined by a mucosal break of 5 mm or greater in diameter with unequivocal depth, and erosion by mucosal change covered with white necrotic substance of less than 5 mm in diameter. The longer diameter of the lesion was measured as a standard of the length that opened biopsy forceps of 6 mm.

Study organization {#Sec7}
------------------

The study design was formulated by the Organizing Committee (see [Appendix](#Sec26){ref-type="sec"}), and data were collected through an Internet-based system.

Statistical analysis {#Sec8}
--------------------

Results were expressed as mean ± SD. Categorical variables between two groups were analyzed with Fisher's exact test, and the means of unpaired continuous variables, by Welch's *t* test. The prevalence and 95 % confidence interval (CI) were estimated by using the binomial distribution. The risk of gastroduodenal ulcer or erosion was estimated by the OR with 95 % CI by using univariate and multivariate logistic regression models. In the multivariate model, the odds ratio was adjusted by suspected risk factors such as age, sex, current tobacco smoking, alcohol use, diabetes mellitus, the presence of *H. pylori* antibody, and history of peptic ulcer, and uses of enteric-coated aspirin, PPI, H2RA, cytoprotective antiulcer drugs. A *p* \< 0.05 was considered as statistically significant. Statistical analyses were performed by using the software R 2.14.0 (R foundation for Statistical Computing, Vienna, Austria).

Role of the funding source {#Sec9}
--------------------------

The sponsor foundation had no role on the study design, selection of study institutions, selection of the committee members, data analyses, or the writing of the manuscript.

Results {#Sec10}
=======

Baseline characteristics of the patients {#Sec11}
----------------------------------------

Among 1,531 patients who were consented and enrolled in the present study, 39 patients refused endoscopy and withdrew the consent, and remaining 1,492 patients received endoscopy. Data of 1,454 participants were used for analysis excluding those of 38 patients for gastric cancer, esophageal cancer, or colon cancer (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow chart of the study patients

The mean participants' age was 68.1 ± 9.5 years, and 73.5 % of the participants were male. Aspirin was received daily for a mean duration of 4.6 ± 4.4 years (Table [1](#Tab1){ref-type="table"}). A total of 89.4 % received enteric-coated aspirin and 10.6 %, buffered aspirin. The majority of the patients took 100 mg daily of enteric-coated aspirin (92.8 %), and 81 mg daily of buffered aspirin (96.2 %). Other NSAIDs were concomitantly used in only 6.5 %.Table 1Baseline patient characteristicsTotal\
(*n* = 1454)AMB\
(*n* = 935) (64.3 %)Erosion\
(*n* = 425) (29.2 %)*p* value^a^Ulcer\
*n* = 94 (6.5 %)*p* value^b^Age (year)68.1 ± 9.568.8 ± 9.567.3 ± 9.30.006065.1 ± 10.20.0009Men (%)1068 (73.5)669 (71.6)320 (75.3)0.167879 (84.0)0.0103Body weight (kg)62.6 ± 11.062.0 ± 11.163.3 ± 10.60.052264.4 ± 12.20.0722Height (cm)161.4 ± 8.5160.9 ± 8.5162.3 ± 8.40.0047162.4 ± 7.90.0689Body mass index (kg/m^2^)23.9 ± 3.223.9 ± 3.224.0 ± 3.10.602124.3 ± 3.40.2780Underlying disease Cerebrovascular disease (%)626 (43.1)395 (42.2)192 (45.2)0.316039 (41.5)0.9132 Coronary artery disease (%)711 (48.9)458 (49.0)199 (46.8)0.482554 (57.4)0.1301 Atrial fibrillation (%)155 (10.7)108 (11.6)41 (9.6)0.34896 (6.4)0.1662Comorbidity Hypertension (%)1053 (72.4)674 (72.1)306 (72.0)1.000073 (77.7)0.2763 Hyperlipidemia (%)830 (57.1)522 (55.8)253 (59.5)0.214855 (58.5)0.6635 Diabetes mellitus (%)416 (28.6)249 (26.6)137 (32.2)0.037830 (31.9)0.2749 Metabolic syndrome (%)779 (53.6)489 (52.3)235 (55.3)0.319255 (58.5)0.2789 *H. pylori* antibody positive (%)700 (48.1)509 (54.4)132 (31.1)\<0.000159 (62.8)0.1546 Others concurrent disease (%)650 (44.7)429 (45.9)180 (42.4)0.239541 (43.6)0.7448 Previous history of peptic ulcer (%)311 (21.4)202 (21.6)83 (19.5)0.429226 (27.7)0.1925Habit Current tobacco smoking (%)151 (10.4)100 (10.7)32 (7.5)0.075219 (20.2)0.0102 Alcohol use (%)591 (40.6)364 (38.9)181 (42.6)0.210346 (48.9)0.0611 Coffee consumption (%)767 (52.8)482 (51.6)233 (54.8)0.266352 (55.3)0.5169Aspirin use Enteric-coated aspirin (%)1300 (89.4)861 (92.1)361 (84.9)0.000178 (83.0)0.0063 Duration of aspirin use (year)4.6 ± 4.44.5 ± 4.44.7 ± 4.40.46795.0 ± 4.70.2924Concomitant drug Other antiplatelet (%)355 (24.4)228 (24.4)107 (25.2)0.786020 (21.3)0.6128 Anticoagulant (%)175 (12.0)125 (13.4)43 (10.1)0.10927 (7.4)0.1077 Other NSAID (%)94 (6.5)60 (6.4)31 (7.3)0.55933 (3.2)0.2642 Antihypertensive drug (%)1084 (74.6)701 (75.0)312 (73.4)0.546471 (75.5)1.0000 Angiotensin II receptor blocker754 (51.9)478 (51.1)219 (51.5)0.439057 (60.6)1.0000 Lipid-lowering drug (%)753 (51.8)478 (51.1)219 (51.5)0.906956 (59.6)0.1299 HMG-Co A reductase inhibitor682 (46.9)430 (46.0)201 (47.3)0.681551 (54.3)0.1303 Antidiabetic drug (%)275 (18.9)160 (17.1)94 (22.1)0.029721 (22.3)0.2027A total of 1454 participants were categorized into three groups by endoscopy: the group with absence of mucosal break (AMB), the group with gastroduodenal erosion (erosion), and the group with gastroduodenal ulcer (ulcer). The proportion of participants in each demographic category was examined among the three groups. Categorical variables were tested with Fisher's exact test and continuous variables with Welch's two sample *t*-test*AMB* absence of mucosal break^a^ *p* value between AMB and erosion^b^ *p* value between AMB and ulcer

Baseline prevalence of gastroduodenal injury {#Sec12}
--------------------------------------------

The point prevalence of gastroduodenal ulcer was 6.5 % and erosion, 29.2 % (Table [1](#Tab1){ref-type="table"}).

Among 94 patients with ulcer, the majority had gastric ulcer (80 cases, 85.1 %), following duodenal ulcer (10 cases, 10.6 %) and gastroduodenal ulcers (4 cases, 4.3 %).

Mean age was unexpectedly lower in the erosion (67.3 ± 9.3 years) and ulcer groups (65.1 ± 10.2 years) than in the group absent of mucosal break (AMB) (68.8 ± 9.5 years) (*p* = 0.0060 and *p* = 0.0009, respectively). In comparison with the AMB group, the ulcer group had greater proportions of male patients and current smokers (*p* = 0.0103 and *p* = 0.0102, respectively). The prevalence of diabetes mellitus was higher (*p* = 0.0378), and that of *H. pylori* antibody positive was lower only in the erosion group (*p* \< 0.0001). Use of enteric-coated aspirin was significantly lower in the erosion group (84.9 %) and in the ulcer group (83.0 %) than in the AMB group (92.1 %) (*p* = 0.0001 and *p* = 0.0063, respectively).

Risk of gastroduodenal injury {#Sec13}
-----------------------------

According to risk analysis (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}), current smoking and *H. pylori* antibody positive were significant risk factors for ulcer: OR = 1.87 (1.03--3.25, *p* = 0.0321) and OR = 1.83 (95 % CI 1.18--2.88, *p* = 0.0082), respectively. However, a reduced risk of erosion was found with *H. pylori* antibody positive: OR = 0.34 (0.26--0.44, *p* \< 0.0001), and a reduced risk of ulcer was found in the elderly population (\>65 years old): OR = 0.60 (0.39--0.94, *p* = 0.0246). The risk for erosion but not for ulcer was significantly lower in use of enteric-coated aspirin (OR = 0.47, 0.32--0.70, *p* = 0.0002) than in use of buffered aspirin (OR = 0.57, 0.32--1.05, *p* = 0.0569).Table 2Factors associated with risk of gastroduodenal ulcerFactorUnadjusted OR*p* valueAdjusted OR*p* valueAge ≥65 years0.58 (0.38--0.88)0.01090.60 (0.39--0.94)0.0246Men1.94 (1.14--3.55)0.02121.45 (0.81--2.74)0.2261Current tobacco smoking2.20 (1.24--3.71)0.00471.87 (1.03--3.25)0.0321Alcohol use1.44 (0.94--2.20)0.08911.18 (0.75--1.86)0.4736Diabetes mellitus1.25 (0.79--1.94)0.33311.12 (0.52--2.22)0.7526*H. pylori* antibody positive1.87 (1.21--2.91)0.00501.83 (1.18--2.88)0.0082History of peptic ulcer1.48 (0.91--2.34)0.10631.52 (0.91--2.47)0.0988Enteric-coated aspirin0.53 (0.31--0.97)0.02850.57 (0.32--1.05)0.0569Proton pump inhibitor0.37 (0.17--0.74)0.00910.34 (0.15--0.68)0.0050H2-receptor antagonist0.80 (0.45--1.35)0.42510.62 (0.34--1.06)0.0967Cytoprotective drug0.93 (0.51--1.61)0.81580.84 (0.45--1.48)0.5703Angiotensin II receptor blocker0.95 (0.62--1.46)0.82110.87 (0.55--1.34)0.5214HMG-Co A reductase inhibitor1.36 (0.90--2.09)0.14891.38 (0.90--2.14)0.1450Antidiabetic drug1.25 (0.74--2.04)0.38011.20 (0.55--2.78)0.6527Factors associated with gastroduodenal injuries suggestive in Table [1](#Tab1){ref-type="table"}, with significant difference and established for gastroduodenal injuries according to previous studies, were examined for risk of gastroduodenal ulcer using data of 1423 participants excluding those without *H. pylori* information. Risk of gastroduodenal ulcer was estimated by the odds ratio with 95 % confidential interval using a monovariate ("Unadjusted") or multivariate ("Adjusted", which adjusted by all listed variables) logistic regression modelTable 3Factors associated with risk of gastroduodenal erosionFactorUnadjusted OR*p* valueAdjusted OR*p* valueAge ≥65 years0.82 (0.64--1.05)0.12100.83 (0.64--1.09)0.1768Men1.23 (0.94--1.61)0.12901.25 (0.93--1.70)0.1413Current tobacco smoking0.69 (0.45--1.04)0.08570.65 (0.41--1.01)0.0597Alcohol use1.19 (0.94--1.50)0.14971.14 (0.87--1.48)0.3447Diabetes mellitus1.30 (1.00--1.67)0.04651.06 (0.69--1.60)0.7917*H. pylori* antibody positive0.38 (0.29--0.48)\<0.00010.34 (0.26--0.44)\<0.0001History of peptic ulcer0.94 (0.70--1.25)0.65991.05 (0.77--1.43)0.7597Enteric-coated aspirin0.47 (0.33--0.67)\<0.00010.47 (0.32--0.70)0.0002Proton pump inhibitor0.44 (0.32--0.61)\<0.00010.32 (0.22--0.46)\<0.0001H2-receptor antagonist0.60 (0.44--0.81)0.00100.49 (0.36--0.68)\<0.0001Cytoprotective antiulcer drug1.12 (0.82--1.51)0.47761.01 (0.72--1.39)0.9592Angiotensin II receptor blocker1.12 (0.88--1.42)0.34961.21 (0.94--1.56)0.1339HMG-Co A reductase inhibitor1.03 (0.81--1.30)0.81591.05 (0.82--1.35)0.6838Antidiabetic drug1.34 (1.00--1.78)0.04841.27 (0.79--2.05)0.3289Factors associated with gastroduodenal injuries suggestive in Table [1,](#Tab1){ref-type="table"} with significant difference and established for gastroduodenal injuries according to previous studies, were examined for risk of gastroduodenal erosion using data of 1330 participants excluding those without *H. pylori* information and with ulcer. Risk of gastroduodenal erosion was estimated by the odds ratio with 95 % confidential interval using a monovariate ("Unadjusted") or multivariate ("Adjusted", which adjusted by all listed variables) logistic regression model

In the analysis of 690 patients not treated with antiulcer drugs, the prevalence of ulcer and erosion were significantly lower with use of enteric-coated aspirin (7.8 and 33.5 %, respectively) than with use of buffered aspirin (12.8 and 47.4 %, respectively) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Use of aspirin formulations and prevalence of gastroduodenal ulcer and erosion in patients not treated with antiulcer drugs. In 690 participants who were not treated with antiulcer drugs, prevalence of gastroduodenal erosion and ulcer were compared between patients receiving enteric-coated (88.7 %) and buffered aspirin (11.3 %). *AMB* absence of mucosal break

Antiulcer drug therapy {#Sec14}
----------------------

Anti-ulcer drugs were prescribed for gastroprotection in 52.5 %. PPI, H2RA, and cytoprotective antiulcer drugs or their combination were used with similar rates, whereas use of PGA or its combination was much lower. Use of PPI alone was lower in the erosion group (10.1 %) and in the ulcer group (7.4 %) than in the AMB group (20.6 %) (*p* \< 0.0001, *p* = 0.0014, respectively). However, the difference in use of H2RA was detected only in the erosion group. Moreover, use of cytoprotective antiulcer drugs was higher in the erosion group (*p* = 0.0364). In analyses, risks of both ulcer and erosion were significantly reduced with PPI therapy (OR = 0.34, 0.15--0.68, *p* = 0.0050 and OR = 0.32, 0.22--0.46, *p* \< 0.0001, respectively). However, in the H2RA therapy group the risk of erosion but not of ulcer was reduced (OR = 0.49, 0.36--0.68, *p* \< 0.0001). No relation was found between therapy with cytoprotective drugs and those risks (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}).Table 4Relationship between aspirin-associated gastroduodenal injuries and antiulcer drug treatmentTotal\
*n* = 1454AMB\
*n* = 935 (64.3)Erosion\
*n* = 425 (29.2)*p* value^a^Ulcer\
*n* = 94 (6.5)*p* value^b^No antiulcer drug (%)690 (47.5)390 (41.7)242 (56.9)\<0.000158 (61.7)0.0003PPI alone (%)243 (16.7)193 (20.6)43 (10.1)\<0.00017 (7.4)0.0014H2RA alone (%)263 (18.1)192 (20.5)58 (13.6)0.002513 (13.8)0.1367CAD alone (%)171 (11.8)98 (10.5)62 (14.6)0.036411 (11.7)0.7246PGA alone (%)2 (0.1)1 (0.1)1 (0.2)0.52750 (0.0)1.0000PPI + H2RA (%)2 (0.1)1 (0.1)1 (0.2)0.52750 (0.0)1.0000PPI + CAD (%)33 (2.3)26 (2.8)7 (1.6)0.25580 (0.0)0.1606PPI + PGA (%)1 (0.1)0 (0.0)0 (0.0)1.00001 (1.1)0.0914CAD + PGA (%)1 (0.1)0 (0.0)1 (0.2)0.31250 (0.0)1.0000H2RA + CAD (%)47 (3.2)34 (3.6)9 (2.1)0.18034 (4.3)0.7716PPI + H2RA + CAD (%)1 (0.1)0 (0.0)1 (0.2)0.31250 (0.0)1.0000Association of gastroduodenal injuries with concomitant use of antiulcer drug was analyzed using data of 1454 participants. The proportions of participants who received each category of antiulcer treatment were examined in the three groups of gastroduodenal conditions. Those in each treatment category were evaluated between the erosion group or the ulcer group versus the AMB group with Fisher's exact test*PPI* proton pump inhibitor, *H2RA* histamine 2-receptor antagonist, *CAD* cytoprotective antiulcer drug, *PGA* prostaglandin analog^a^ *p* value between AMB and Erosion^b^ *p* value between AMB and Ulcer

Upper GI cancer {#Sec15}
---------------

Among 1,492 participants who received endoscopy, 37 participants (2.5 %, 95 % CI 1.75--3.40) had upper GI cancer, 4 patients (0.27 %, 0.07--0.68) had esophageal cancer, and 33 patients (2.21 %, 95 % CI 1.53--3.09) had gastric cancer. Additionally, colon cancer was found in one patient.

Discussion {#Sec16}
==========

Our study demonstrated that endoscopic gastroduodenal injuries were prevalent (35.7 %) among low-dose aspirin users in Japan, similar to Western countries. However, significant differences were found between the two regions in the methods aspirin was prescribed and the risk factors and drug treatment for gastroduodenal injuries. Use of other NSAIDs (6.5 %) with aspirin was rare in the present study, while it is frequent in Western countries. In spite of the recommendations in the AHA consensus and Japanese guidelines \[[@CR12], [@CR13]\], the use of PPI treatment was relatively low (19 %) and was similar to the use of H2RA or cytoprotective antiulcer agents. Cytoprotective agents are not generally used in Western countries. The recent approval (2010) of PPI for the prevention of mucosal injury in Japan may be contributing to the low PPI use.

Prevalence of gastroduodenal ulcer and erosion {#Sec17}
----------------------------------------------

The prevalence of endoscopic gastroduodenal ulcer associated with low-dose aspirin (6.5 %) was lower in our study than in previous studies. The prevalence of ulcer and erosion were 18 and 42 %, respectively, among 101 Japanese patients with ischemic heart disease in the study of Nema et al. \[[@CR14]\], while that of upper GI ulcer was 12.4 % in 305 Japanese patients in the study of Shiotani et al. \[[@CR15]\]. According to Yeomans et al., the point prevalence was 11 % for endoscopic gastroduodenal ulcer and 63 % for erosion in 187 patients taking aspirin for at least 24 days \[[@CR4]\]. Factors contributing to the lower prevalence of ulcer or erosion in our study may be as follows: (1) a total of 41 % of the participants were treated with PPI or H2RA; (2) concomitant use of other NSAIDs was much lower; and (3) the criterion for mucosal ulcer was a mucosal break of 5 mm or greater in diameter with unequivocal depth. Nonetheless, by our estimation the prevalence of low-dose aspirin-induced endoscopic gastroduodenal ulcer in Japan is approximately 5--10 % in clinical practice.

Risk factors for gastroduodenal ulcer and erosion {#Sec18}
-------------------------------------------------

Clinically important risk factors for aspirin-associated upper GI bleeding include aging, history of peptic ulcer or GI bleeding, concomitant use of anticoagulants or NSAIDs, and *H. pylori* infection in Western populations \[[@CR16]\]. However, a limited number of studies endoscopically examined ulcer risk factors \[[@CR15], [@CR17]\]. In a study of Shiotani et al. \[[@CR17]\] aging, history of peptic ulcer, and concomitant use of antithrombotic drugs and NSAIDs were associated with peptic ulcer, but regular alcohol drinking, smoking, and *H. pylori* infection were not in 425 low-dose aspirin users. In our study, a history of peptic ulcer, and the concomitant use of anticoagulants and NSAIDs had little association with endoscopic gastroduodenal ulcer and erosion. The reason may include (1) elderly patients with high risk for peptic ulcer such as those taking concomitant anticoagulants and NSAIDs might not be recruited, and (2) the number of concomitant NSAID use in this study was small, which may lead to an underestimation of the risk.

Aging was a risk factor for low-dose aspirin related gastroduodenal ulcer in many studies \[[@CR4], [@CR16], [@CR17]\], whereas we observed that age \>65 years old was associated a significant reduction in the risk of aspirin-associated ulcer. Furthermore in the analysis of 690 patients not treated with antiulcer drugs, the prevalence of ulcer was significantly lower in the elderly population (See the Supplementary table). The consensus of prior data is that risk of aspirin-associated ulcer increases with advancing age. This means that there may be a significant bias in our methodology or the Japanese may differ in gastric physiology from the rest of the world. In Japanese populations, the older generation has significantly reduced gastric acid secretion compared to younger generations due to atrophic gastritis \[[@CR18]\]. Therefore, younger generations may have an inherently higher acid secretion and thus a higher risk of ulcers. However, the age-associated increase in atrophic gastritis is not specific gastritis is not a phenomenon which is specific to Japanese patients. Therefore, it is very likely to be a significant bias in our methodology that elderly patients with at high risk for peptic ulcer might not be recruited.

According to studies of Western populations, the presence of *H. pylori* infection is a significant risk for gastroduodenal ulcer \[[@CR19]\]. Our study also demonstrated a twofold increase in ulcer risk in the presence versus the absence of *H. pylori* antibody. However, those results were conflicting with those of Shiotani et al. \[[@CR15], [@CR17]\] in Japanese populations where *H. pylori* infection was not associated with peptic ulcer in low-dose aspirin users. The findings may be affected by the study population and the definition of ulcer, which will be discussed in a separate section. In our study, the risk of erosion was significantly lower in the presence of *H. pylori* antibody. The cause and pathogenesis of aspirin-induced endoscopic gastroduodenal ulcer may be different from those of erosion in the presence of *H. pylori* infection.

Aspirin formulation {#Sec19}
-------------------

The prevalence of gastroduodenal injuries was significantly lower with enteric-coated aspirin than with buffered aspirin in our study. Others found that the risks of upper GI bleeding were similar among three forms of aspirin \[[@CR20]\]. Although the prevalence of endoscopic gastroduodenal erosion was significantly lower with enteric-coated aspirin than with buffered aspirin, ulcer frequency was similar between the two formulations in the study of Nema et al. \[[@CR21]\]. Dammann et al. \[[@CR22]\] demonstrated that endoscopic gastroduodenal mucosal lesions were significantly less likely with enteric-coated aspirin (100 mg/day) than with plain aspirin, and the lesion score with coated aspirin was similar to that of placebo without aspirin. Further studies on the influence of aspirin formulation are needed in Japan.

Antiulcer drugs for prevention of gastroduodenal injury {#Sec20}
-------------------------------------------------------

Use of PPI was significantly less in the patients with ulcer or erosion, whereas use of H2RA was less in the patients with erosion, but not with ulcer. Use of cytoprotective drugs, which are widely prescribed in Japan, was higher in the patients with erosion. According to the risk analyses, only PPI presents reduced risks of both ulcer and erosion. The usefulness of PPI in the prevention of ulcers induced by low-dose aspirin is well established in Western countries and in Japan. In a comparative study by Yeomans et al. \[[@CR23]\] the development of gastrointestinal ulcer was lower (1.6 %) with esomeprazole 20 mg/day than with placebo (5.4 %), demonstrating a reduction of 70 % in the 991 participants aged ≥60 years receiving low-dose aspirin for 26 weeks without preexisting endoscopic ulcers and without concomitant NSAIDs. Although their study design differed from ours, their findings support our study results. The effectiveness of PPI for the prevention of low-dose aspirin associated gastric or duodenal ulcers was demonstrated in a randomized comparative study by Sugano et al. \[[@CR24]\] of a PPI, lansoprazole (15 mg/day), versus a cytoprotective antiulcer drug, gefarnate (100 mg/day), for secondary prevention. The recurrence of ulcers was 90 % lower with lansoprazole than with gefarnate for an administration of 12 months or longer. According to Taha et al. \[[@CR25]\] H2RA treatment with famotidine for 20 weeks reduced the risk of aspirin-induced peptic ulcer by 80 %. However, the risk of gastroduodenal erosion but not of ulcer was significantly lower with H2RA in our study. Study design and the ethnicity of the study populations may have contributed to the difference in results between the two studies.

Definition of ulcer and erosion as surrogate marker {#Sec21}
---------------------------------------------------

Endoscopic gastroduodenal ulcer has been suggested to be a useful surrogate marker for potentially serious aspirin adverse event such as GI bleeding \[[@CR26]\]. However, as described by Graham \[[@CR27]\], ulcers are often defined by a mucosal defect of "3 mm or more" or "5 mm or more" in diameter in clinical studies, but aspirin-induced ulcer is often difficult to distinguish from erosion. No internationally recognized clear definition of "ulcer" or "a method of measuring ulcer size" has been established. Our definition of endoscopic ulcer was a mucosal defect 5 mm or more in diameter. However, when an ulcer with a 10 mm or larger diameter is defined as a "large ulcer," 25 % or more of ulcers were large ulcers in patients receiving H2RA or a cytoprotective antiulcer drug, but none of the ulcers were large ulcers in those receiving PPI in the present study (data not shown). Thus, the size of ulcers must be carefully defined for assessing effectiveness of antiulcer drugs in clinical studies that use endoscopically defined ulcers as the primary endpoint. A large cohort study is needed to clarify the risk factors of serious adverse events such as GI bleeding, and to verify endoscopically defined ulcer as a useful surrogate marker of GI bleeding in low-dose aspirin users.

Gastric cancer {#Sec22}
--------------

This is the first study reporting the prevalence of gastric cancer diagnosed by endoscopy among aspirin users. Among 1,492 patients who received endoscopy, 37 patients had gastric cancer (2.5 %). Reports on the possible prevention of gastric cancer with aspirin have been published \[[@CR28], [@CR29]\], but it seems that more studies are necessary in the regions with a high prevalence of gastric cancer, such as Japan.

Limitation {#Sec23}
----------

We did not conduct the systematic screening in each hospital for patient recruitment. Our registry recruited patients taking preventive aspirin for high risk CV in clinical practice and gave informed consent to this study. Inclusion bias may be a potential limitation of this study.

Conclusion {#Sec24}
==========

Gastroduodenal ulcer and erosion are common among patients receiving low-dose aspirin for prophylaxis of CV disease in the Japanese population (35.7 %). Factors that increase risks of mucosal injuries are current tobacco smoking and the presence of *H. pylori* infection. The use of PPI is helpful to reduce the risk of ulcer and erosion. Furthermore, the association between endoscopic ulcer and serious complications such as GI bleeding should be clarified in the future.
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